CBIO

Crescent Biopharma Inc

• Reuters·03/27 20:21

  Crescent Biopharma grants inducement options for 35,325 shares; exercise price set at $13.50

• Benzinga·03/17 20:32

  Crescent Biopharma Files Prospectus For Resale Of Up To ~19.7M Shares By Selling Securityholders From Private Placement And Warrants

• Reuters·03/17 20:25

  CRESCENT BIOPHARMA INC - FILES FOR PROSPECTUS OF RESALE OF UP TO 19.6 MLN ORDINARY SHARES OFFERED BY SELLING SECURITYHOLDERS - SEC FILING

• Reuters·03/06 21:18

  Crescent Biopharma Grants Inducement Stock Options Under 2025 Incentive Plan

• Dow Jones·03/02 14:20

  Crescent Biopharma Price Target Cut to $22.00/Share From $25.00 by HC Wainwright & Co.

• Dow Jones·03/02 14:20

  Crescent Biopharma Is Maintained at Buy by HC Wainwright & Co.

• Benzinga·03/02 14:10

  HC Wainwright & Co. Maintains Buy on Crescent Biopharma, Lowers Price Target to $22

• TipRanks·03/02 11:44

  Crescent Biopharma price target lowered to $22 from $25 at H.C. Wainwright

• TipRanks·02/27 12:58

  Guggenheim Remains a Buy on Crescent Biopharma (CBIO)

• TipRanks·02/26 21:50

  Analysts Offer Insights on Healthcare Companies: Crescent Biopharma (CBIO) and Viridian Therapeutics (VRDN)

• TipRanks·02/26 18:10

  Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Crescent Biopharma (CBIO)

• TipRanks·02/26 12:49

  Crescent Biopharma reports Q4 EPS ($4.01) vs. ($19.74) last year

• TipRanks·02/26 12:48

  Crescent Biopharma sees cash runway into 2028

• Dow Jones·02/26 12:32

  *Crescent Biopharma 4Q Rev $10.8M >CBIO

• Dow Jones·02/26 12:32

  *Crescent Biopharma 4Q Research and Development Expenses $95.0M >CBIO